Skip to content
Intrommune is supported by the Allergy & Asthma Network
More Information
Intrommune is supported by the Allergy & Asthma Network
More Information
About Us
Overview
Company Leadership
Intrommune R&D
Food Allergies
Oral Mucosal Immunotherapy
INT301 for Peanut Allergy
Media
Press Releases
Events
Intrommune in the News
Investors
Videos
White Paper
Contact Us
Newsletter
Sign up for Intrommune's newsletter and stay informed of company developments.
Intrommune in the News
March 2021
Drug Development & Delivery: Oral Mucosal Delivery of Allergenic Proteins for Inducing Tolerance in Food Allergic Individuals
March 2021
Daily Mail: Peanut Allergies Could Get The Brush Off In Toothpaste Trial
March 2021
Intrommune Therapeutics selected as a “Winning Startup” in The Innovate Children’s Health Challenge (ICHC)
List of Challenge Winners
March 2021
Interesting Engineering: Experimental Toothpaste Might Treat Peanut Allergy
March 2021
Nerdist: A New Toothpaste May Help Treat Peanut Allergies
March 2021
Science News: An experimental toothpaste aims to treat peanut allergy
February 2021
Chief Science Officer Erick Berglund interviewed on the Price of Business with Kevin Price
February 2021
Global Data publishes profile of Intrommune Therapeutics’ Phase Ib study and its Series B raise
January 2021
Intrommune presentation at the H.C. Wainwright BioConnect 2021 Conference by Dr. Abhit Singh
December 2020
William Reisacher, MD’s article in Coping with Allergies & Asthma: Five Things you Should Know about Peanut Allergy Immunotherapy
November 2020
Intrommune CEO, Michael Nelson, spoke with PetaCrunch about Intrommune’s approach to treating peanut allergies
October 2020
Intrommune selected as Semifinalist in the Innovate Children’s Health Challenge
March 2020
Senior Medical Advisor, William Reisacher, interviewed on the Price of Business with Kevin Price
January 2020
Proactive Interview: Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process
September 2019
Providing Innovative Treatments for Peanut Allergies
Intrommune CEO, Michael Nelson, interview on the Price of Business with Kevin Price
September 2019
Science News: Liquid mouth drops could one day protect people from peanut allergies
Octoberber 2018
Intrommune Therapeutics selected as one of the RESI NYC Innovation Challenge Finalists
July 2018
Intrommune Senior Scientific Advisor, Dr. Reisacher, featured in SELF article: Southwest Airlines Is Finally Getting Rid of In-Flight Peanuts
June 2018
Q&A with Michael Nelson, JD, Co-Founder and CEO of Intrommune Therapeutics
developing a revolutionary new Drug Delivery method using Toothpaste to
Deliver an Oral Mucosal Immunotherapy for People who have a Peanut Allergy
May 2018
New Idea for Immunotherapy–an Interview with Dr. Toothpaste
About Us
Overview
Company Leadership
Intrommune R&D
Food Allergies
Oral Mucosal Immunotherapy
INT301 for Peanut Allergy
Media
Press Releases
Events
Intrommune in the News
Investors
Videos
White Paper
Contact Us
Intrommune is supported by the Allergy & Asthma Network
More Information
Login
Username or email address
*
Password
*
Remember me
Log in
Lost your password?